Physician profile
Seema Kumar
NPI 1235662073
$1,557.48
in general payments reported to CMS, 2019-2025
11 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $521 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.49 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $307.73 | 2024-2025 | Tremfya, Stelara |
| Fujifilm Healthcare Americas Corporation | $292.20 | 2025 | |
| Madrigal Pharmaceuticals | $244.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $139.77 | 2025 | Iqirvo |
| Genzyme Corporation | $130.26 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $120.52 | 2024-2025 | Dupixent |
| Abbvie INC. | $95.30 | 2024-2025 | |
| Qol Medical, LLC | $76.72 | 2024-2025 | Sucraid, Sucraid |
| 3-D Matrix, INC. | $74.20 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.26 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.24 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.